Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 48
Filter
Add more filters










Publication year range
1.
J Clin Invest ; 2024 May 07.
Article in English | MEDLINE | ID: mdl-38713514

ABSTRACT

Pancreatic ß-cell dysfunction is a key feature of type 2 diabetes, and novel regulators of insulin secretion are desirable. Here we report that the succinate receptor (SUCNR1) is expressed in ß-cells and is up-regulated in hyperglycemic states in mice and humans. We found that succinate acts as a hormone-like metabolite and stimulates insulin secretion via a SUCNR1-Gq-PKC-dependent mechanism in human ß-cells. Mice with ß-cell-specific Sucnr1 deficiency exhibit impaired glucose tolerance and insulin secretion on a high-fat diet, indicating that SUCNR1 is essential for preserving insulin secretion in diet-induced insulin resistance. Patients with impaired glucose tolerance show an enhanced nutritional-related succinate response, which correlates with the potentiation of insulin secretion during intravenous glucose administration. These data demonstrate that the succinate/SUCNR1 axis is activated by high glucose and identify a GPCR-mediated amplifying pathway for insulin secretion relevant to the hyperinsulinemia of prediabetic states.

2.
Mar Drugs ; 22(4)2024 Apr 15.
Article in English | MEDLINE | ID: mdl-38667793

ABSTRACT

Tetrodotoxin (TTX) is a marine toxin responsible for many intoxications around the world. Its presence in some pufferfish species and, as recently reported, in shellfish, poses a serious health concern. Although TTX is not routinely monitored, there is a need for fast, sensitive, reliable, and simple methods for its detection and quantification. In this work, we describe the use of an automated patch clamp (APC) system with Neuro-2a cells for the determination of TTX contents in pufferfish samples. The cells showed an IC50 of 6.4 nM for TTX and were not affected by the presence of muscle, skin, liver, and gonad tissues of a Sphoeroides pachygaster specimen (TTX-free) when analysed at 10 mg/mL. The LOD achieved with this technique was 0.05 mg TTX equiv./kg, which is far below the Japanese regulatory limit of 2 mg TTX equiv./kg. The APC system was applied to the analysis of extracts of a Lagocephalus sceleratus specimen, showing TTX contents that followed the trend of gonads > liver > skin > muscle. The APC system, providing an in vitro toxicological approach, offers the advantages of being sensitive, rapid, and reliable for the detection of TTX-like compounds in seafood.


Subject(s)
Patch-Clamp Techniques , Tetraodontiformes , Tetrodotoxin , Tetrodotoxin/analysis , Animals , Seafood/analysis , Mice , Food Contamination/analysis , Limit of Detection
3.
Eur J Med Chem ; 236: 114354, 2022 Jun 05.
Article in English | MEDLINE | ID: mdl-35453065

ABSTRACT

Currently, of the few accessible symptomatic therapies for Alzheimer's disease (AD), memantine is the only N-methyl-d-aspartate receptor (NMDAR) blocker approved by the FDA. This work further explores a series of memantine analogs featuring a benzohomoadamantane scaffold. Most of the newly synthesized compounds block NMDARs in the micromolar range, but with lower potency than previously reported hit IIc, results that were supported by molecular dynamics simulations. Subsequently, electrophysiological studies with the more potent compounds allowed classification of IIc, a low micromolar, uncompetitive, voltage-dependent, NMDAR blocker, as a memantine-like compound. The excellent in vitro DMPK properties of IIc made it a promising candidate for in vivo studies in Caenorhabditis elegans (C. elegans) and in the 5XFAD mouse model of AD. Administration of IIc or memantine improved locomotion and rescues chemotaxis behavior in C. elegans. Furthermore, both compounds enhanced working memory in 5XFAD mice and modified NMDAR and CREB signaling, which may prevent synaptic dysfunction and modulate neurodegenerative progression.


Subject(s)
Alzheimer Disease , Memantine , Alzheimer Disease/drug therapy , Animals , Caenorhabditis elegans , Disease Models, Animal , Memantine/pharmacology , Mice , Receptors, N-Methyl-D-Aspartate
4.
J Alzheimers Dis ; 82(s1): S91-S107, 2021.
Article in English | MEDLINE | ID: mdl-33325386

ABSTRACT

To deeply understand late onset Alzheimer's disease (LOAD), it may be necessary to change the concept that it is a disease exclusively driven by aging processes. The onset of LOAD could be associated with a previous peripheral stress at the level of the gut (changes in the gut microbiota), obesity (metabolic stress), and infections, among other systemic/environmental stressors. The onset of LOAD, then, may result from the generation of mild peripheral inflammatory processes involving cytokine production associated with peripheral stressors that in a second step enter the brain and spread out the process causing a neuroinflammatory brain disease. This hypothesis could explain the potential efficacy of Sodium Oligomannate (GV-971), a mixture of acidic linear oligosaccharides that have shown to remodel gut microbiota and slowdown LOAD. However, regardless of the origin of the disease, the end goal of LOAD-related preventative or disease modifying therapies is to preserve dendritic spines and synaptic plasticity that underlay and support healthy cognition. Here we discuss how systemic/environmental stressors impact pathways associated with the regulation of spine morphogenesis and synaptic maintenance, including insulin receptor and the brain derived neurotrophic factor signaling. Spine structure remodeling is a plausible mechanism to maintain synapses and provide cognitive resilience in LOAD patients. Importantly, we also propose a combination of drugs targeting such stressors that may be able to modify the course of LOAD by acting on preventing dendritic spines and synapsis loss.


Subject(s)
Alzheimer Disease/therapy , Dendritic Spines/physiology , Gastrointestinal Microbiome/drug effects , Mannose/analogs & derivatives , Oligosaccharides/administration & dosage , Synapses/physiology , Alzheimer Disease/metabolism , Alzheimer Disease/psychology , Amyloid beta-Peptides/antagonists & inhibitors , Amyloid beta-Peptides/metabolism , Animals , Dendritic Spines/drug effects , Dendritic Spines/pathology , Diet, Healthy/methods , Diet, Healthy/psychology , Exercise/physiology , Exercise/psychology , Gastrointestinal Microbiome/physiology , Humans , Mannose/administration & dosage , Synapses/drug effects , Synapses/pathology
5.
Harmful Algae ; 99: 101913, 2020 11.
Article in English | MEDLINE | ID: mdl-33218439

ABSTRACT

Gambierdiscus and Fukuyoa are genera of toxic dinoflagellates which were mainly considered as endemic to marine intertropical areas, and that are well known as producers of ciguatoxins (CTXs) and maitotoxins (MTXs). Ciguatera poisoning (CP) is a human poisoning occurring after the consumption of fish or more rarely, shellfish containing CTXs. The presence of these microalgae in a coastal area is an indication of potential risk of CP. This study assesses the risk of CP in the Balearic Islands (Western Mediterranean Sea) according to the distribution of both microalgae genera, and the presence of CTX-like and MTX-like toxicity in microalgal cultures as determined by neuro-2a cell based-assay (neuro-2a CBA). Genetic identification of forty-three cultured microalgal strains isolated from 2016 to 2019 revealed that all of them belong to the species G. australes and F. paulensis. Both species were widely distributed in Formentera, Majorca and Minorca. Additionally, all strains of G. australes and two of F. paulensis exhibited signals of CTX-like toxicity ranging respectively between 1 and 380 and 8-16 fg CTX1B equivalents (equiv.) • cell-1. Four extracts of F. paulensis exhibited a novel toxicity response in neuro-2a cells consisting of the recovery of the cell viability in the presence of ouabain and veratridine. In addition, G. australes showed MTX-like toxicity while F. paulensis strains did not. Overall, the low CTX-like toxicities detected indicate that the potential risk of CP in the Balearic Islands is low, although, the presence of CTX-like and MTX-like toxicity in those strains reveal the necessity to monitor these genera in the Mediterranean Sea.


Subject(s)
Ciguatera Poisoning , Ciguatoxins , Dinoflagellida , Animals , Ciguatoxins/analysis , Ciguatoxins/toxicity , Mediterranean Sea , Spain
6.
Eur J Med Chem ; 180: 613-626, 2019 Oct 15.
Article in English | MEDLINE | ID: mdl-31351393

ABSTRACT

The development of multitarget compounds against multifactorial diseases, such as Alzheimer's disease, is an area of very intensive research, due to the expected superior therapeutic efficacy that should arise from the simultaneous modulation of several key targets of the complex pathological network. Here we describe the synthesis and multitarget biological profiling of a new class of compounds designed by molecular hybridization of an NMDA receptor antagonist fluorobenzohomoadamantanamine with the potent acetylcholinesterase (AChE) inhibitor 6-chlorotacrine, using two different linker lengths and linkage positions, to preserve or not the memantine-like polycyclic unsubstituted primary amine. The best hybrids exhibit greater potencies than parent compounds against AChE (IC50 0.33 nM in the best case, 44-fold increased potency over 6-chlorotacrine), butyrylcholinesterase (IC50 21 nM in the best case, 24-fold increased potency over 6-chlorotacrine), and NMDA receptors (IC50 0.89 µM in the best case, 2-fold increased potency over the parent benzohomoadamantanamine and memantine), which suggests an additive effect of both pharmacophoric moieties in the interaction with the primary targets. Moreover, most of these compounds have been predicted to be brain permeable. This set of biological properties makes them promising leads for further anti-Alzheimer drug development.


Subject(s)
Adamantane/pharmacology , Alzheimer Disease/drug therapy , Cholinesterase Inhibitors/pharmacology , Neuroprotective Agents/pharmacology , Tacrine/analogs & derivatives , Acetylcholinesterase/metabolism , Adamantane/analogs & derivatives , Adamantane/chemistry , Alzheimer Disease/metabolism , Butyrylcholinesterase/metabolism , Cholinesterase Inhibitors/chemical synthesis , Cholinesterase Inhibitors/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/chemistry , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/metabolism , Structure-Activity Relationship , Tacrine/chemistry , Tacrine/pharmacology
7.
Int J Mol Sci ; 21(1)2019 Dec 30.
Article in English | MEDLINE | ID: mdl-31905931

ABSTRACT

Previous studies have reported that the regulatory function of the different c-Jun N-terminal kinases isoforms (JNK1, JNK2, and JNK3) play an essential role in neurological disorders, such as epilepsy and metabolic-cognitive alterations. Accordingly, JNKs have emerged as suitable therapeutic strategies. In fact, it has been demonstrated that some unspecific JNK inhibitors exert antidiabetic and neuroprotective effects, albeit they usually show high toxicity or lack therapeutic value. In this sense, natural specific JNK inhibitors, such as Licochalcone A, are promising candidates. Nonetheless, research on the understanding of the role of each of the JNKs remains mandatory in order to progress on the identification of new selective JNK isoform inhibitors. In the present review, a summary on the current gathered data on the role of JNKs in pathology is presented, as well as a discussion on their potential role in pathologies like epilepsy and metabolic-cognitive injury. Moreover, data on the effects of synthetic small molecule inhibitors that modulate JNK-dependent pathways in the brain and peripheral tissues is reviewed.


Subject(s)
Cognitive Dysfunction/metabolism , Epilepsy/metabolism , JNK Mitogen-Activated Protein Kinases/metabolism , Animals , Brain/metabolism , Cognitive Dysfunction/pathology , Diabetes Mellitus, Type 2/metabolism , Endoplasmic Reticulum Stress , Epilepsy/pathology , Humans , Hypoglycemic Agents/antagonists & inhibitors , JNK Mitogen-Activated Protein Kinases/drug effects , MAP Kinase Signaling System/physiology , Mitochondria/metabolism , Mitogen-Activated Protein Kinases/metabolism , Neuroprotective Agents/antagonists & inhibitors , Protein Isoforms
9.
Neurotherapeutics ; 16(2): 416-431, 2019 04.
Article in English | MEDLINE | ID: mdl-30460457

ABSTRACT

As populations increase their life expectancy, age-related neurodegenerative disorders such as Alzheimer's disease have become more common. I2-Imidazoline receptors (I2-IR) are widely distributed in the central nervous system, and dysregulation of I2-IR in patients with neurodegenerative diseases has been reported, suggesting their implication in cognitive impairment. This evidence indicates that high-affinity selective I2-IR ligands potentially contribute to the delay of neurodegeneration. In vivo studies in the female senescence accelerated mouse-prone 8 mice have shown that treatment with I2-IR ligands, MCR5 and MCR9, produce beneficial effects in behavior and cognition. Changes in molecular pathways implicated in oxidative stress, inflammation, synaptic plasticity, and apoptotic cell death were also studied. Furthermore, treatments with these I2-IR ligands diminished the amyloid precursor protein processing pathway and increased Aß degrading enzymes in the hippocampus of SAMP8 mice. These results collectively demonstrate the neuroprotective role of these new I2-IR ligands in a mouse model of brain aging through specific pathways and suggest their potential as therapeutic agents in brain disorders and age-related neurodegenerative diseases.


Subject(s)
Aging/drug effects , Behavior, Animal/drug effects , Cognition/drug effects , Hippocampus/drug effects , Imidazoline Receptors/agonists , Aging/metabolism , Amyloid beta-Protein Precursor/metabolism , Animals , Apoptosis/drug effects , Disease Models, Animal , Female , Hippocampus/metabolism , Mice , Oxidative Stress/drug effects , Recognition, Psychology/drug effects
10.
ACS Chem Neurosci ; 9(11): 2722-2730, 2018 11 21.
Article in English | MEDLINE | ID: mdl-29767953

ABSTRACT

This work reports the synthesis and pharmacological and electrophysiological evaluation of new N-methyl-d-aspartic acid receptor (NMDAR) channel blocking antagonists featuring polycyclic scaffolds. Changes in the chemical structure modulate the potency and voltage dependence of inhibition. Two of the new antagonists display properties comparable to those of memantine, a clinically approved NMDAR antagonist.


Subject(s)
Excitatory Amino Acid Antagonists/chemical synthesis , Neurons/drug effects , Polycyclic Compounds/chemical synthesis , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Amines/chemical synthesis , Amines/pharmacology , Animals , Cerebellum/cytology , Excitatory Amino Acid Antagonists/pharmacology , Inhibitory Concentration 50 , Memantine/pharmacology , Patch-Clamp Techniques , Polycyclic Compounds/pharmacology , Rats , Structure-Activity Relationship
11.
Molecules ; 23(1)2018 Jan 21.
Article in English | MEDLINE | ID: mdl-29361735

ABSTRACT

Multi-target-directed ligands (MTDLs) offer new hope for the treatment of multifactorial complex diseases such as Alzheimer's Disease (AD). Herein, we present compounds aimed at targeting the NMDA and the P2X7 receptors, which embody a different approach to AD therapy. On one hand, we are seeking to delay neurodegeneration targeting the glutamatergic NMDA receptors; on the other hand, we also aim to reduce neuroinflammation, targeting P2X7 receptors. Although the NMDA receptor is a widely recognized therapeutic target in treating AD, the P2X7 receptor remains largely unexplored for this purpose; therefore, the dual inhibitor presented herein-which is open to further optimization-represents the first member of a new class of MTDLs.


Subject(s)
Purinergic P2X Receptor Antagonists/chemistry , Purinergic P2X Receptor Antagonists/pharmacology , Receptors, Purinergic P2X/chemistry , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Cell Line, Tumor , Chemistry Techniques, Synthetic , Dose-Response Relationship, Drug , Drug Design , Drug Discovery , Humans , Inhibitory Concentration 50 , Ligands , Molecular Structure , Purinergic P2X Receptor Antagonists/chemical synthesis , Receptors, Purinergic P2X/metabolism
12.
Pharmacol Rep ; 69(3): 409-418, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28273500

ABSTRACT

BACKGROUND: In the present work, we studied the modulatory effect of Leptin (Lep) against pro-inflammatory cytokines, tumour necrosis factor-alpha (TNFα), interleukin 1-beta (IL1ß) and interferon-gamma (IFNγ), in primary glial cell cultures. METHODS: Glial cultures were treated with pro-inflammatory cytokines (TNFα, 20ng/ml; IL1ß, 20ng/ml; IFNγ 20ng/ml). Cells were pre-treated with Lep 500nM, 1h prior to cytokine treatment. NO released from glial cells was determined using the Griess reaction. Cell viability was determined by the MTT method. Protein expression was determined by western blot. RESULTS: Pre-treatment with 500nM Lep produced an inhibitory effect on inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production after glial cells exposure to pro-inflammatory cytokines. Anti-inflammatory effect can be related to a decrease in P38 MAP Kinase (MAPK) pathway activity. Treatment of glial cell cultures with Lep also reduced the intrinsic apoptotic pathway (cytochrome c release and caspase-3 activation). CONCLUSIONS: We suggest that Lep would act as an anti-inflammatory factor in glial cells exposed to pro-inflammatory cytokines, exerting its function on p38 MAPK pathway and reducing NO production.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Inflammation/drug therapy , Leptin/pharmacology , p38 Mitogen-Activated Protein Kinases/metabolism , Animals , Anti-Inflammatory Agents/administration & dosage , Apoptosis/drug effects , Cell Survival/drug effects , Cells, Cultured , Cytokines/administration & dosage , Cytokines/metabolism , Disease Models, Animal , Inflammation/pathology , Interferon-gamma/administration & dosage , Interferon-gamma/metabolism , Interleukin-1beta/administration & dosage , Interleukin-1beta/metabolism , Leptin/administration & dosage , MAP Kinase Signaling System/drug effects , Mice , Mice, Inbred C57BL , Neuroglia/drug effects , Neuroglia/pathology , Nitric Oxide/metabolism , Tumor Necrosis Factor-alpha/administration & dosage , Tumor Necrosis Factor-alpha/metabolism
13.
Molecules ; 21(8)2016 Aug 06.
Article in English | MEDLINE | ID: mdl-27509489

ABSTRACT

Enantiopure tryptophanol is easily obtained from the reduction of its parent natural amino acid trypthophan (available from the chiral pool), and can be used as chiral auxiliary/inductor to control the stereochemical course of a diastereoselective reaction. Furthermore, enantiopure tryptophanol is useful for the syntheses of natural products or biological active molecules containing the aminoalcohol functionality. In this communication, we report the development of a small library of indolo[2,3-a]quinolizidines and evaluation of their activity as N-Methyl d-Aspartate (NMDA) receptor antagonists. The indolo[2,3-a]quinolizidine scaffold was obtained using the following key steps: (i) a stereoselective cyclocondensation of (S)- or (R)-tryptophanol with appropriate racemic δ-oxoesters; (ii) a stereocontrolled cyclization on the indole nucleus. The synthesized enantiopure indolo[2,3-a]quinolizidines were evaluated as NMDA receptor antagonists and one compound was identified to be 2.9-fold more potent as NMDA receptor blocker than amantadine (used in the clinic for Parkinson's disease). This compound represents a hit compound for the development of novel NMDA receptor antagonists with potential applications in neurodegenerative disorders associated with overactivation of NMDA receptors.


Subject(s)
Quinolizidines/chemical synthesis , Quinolizidines/pharmacology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Cyclization , Indoles/chemical synthesis , Indoles/chemistry , Indoles/pharmacology , Molecular Structure , Quinolizidines/chemistry , Small Molecule Libraries/chemical synthesis , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology , Stereoisomerism , Tryptophan/analogs & derivatives , Tryptophan/chemistry
14.
Front Biosci (Landmark Ed) ; 21(1): 8-19, 2016 01 01.
Article in English | MEDLINE | ID: mdl-26709757

ABSTRACT

Recent studies suggest that the neurobiology of Alzheimer's disease (AD) pathology could not be explained solely by an increase in beta-amyloid levels. In fact, success with potential therapeutic drugs that inhibit the generation of beta amyloid has been low. Therefore, due to therapeutic failure in recent years, the scientists are looking for alternative hypotheses to explain the causes of the disease and the cognitive loss. Accordingly, alternative hypothesis propose a link between AD and peripheral metabolic alteration. Then, we review in depth changes related to insulin signalling and energy metabolism in the context of the APPSwe/PS1dE9 (APP/PS1) mice model of AD. We show an integrated view of the changes that occur in the early stages of the amyloidogenic process in the APP/PS1 double transgenic mice model. These early changes affect several key metabolic processes related to glucose uptake and insulin signalling, cellular energy homeostasis, mitochondrial biogenesis and increased Tau phosphorylation by kinase molecules like mTOR and Cdk5.


Subject(s)
Alzheimer Disease/metabolism , Energy Metabolism , Metabolic Syndrome/metabolism , Adipokines/metabolism , Humans
15.
Biochim Biophys Acta ; 1852(9): 1687-99, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26003667

ABSTRACT

Global obesity is a pandemic status, estimated to affect over 2 billion people, that has resulted in an enormous strain on healthcare systems worldwide. The situation is compounded by the fact that apart from the direct costs associated with overweight pathology, obesity presents itself with a number of comorbidities, including an increased risk for the development of neurodegenerative disorders. Alzheimer disease (AD), the main cause of senile dementia, is no exception. Spectacular failure of the pharmaceutical industry to come up with effective AD treatment strategies is forcing the broader scientific community to rethink the underlying molecular mechanisms leading to cognitive decline. To this end, the emphasis is once again placed on the experimental animal models of the disease. In the current study, we have focused on the effects of a high-fat diet (HFD) on hippocampal-dependent memory in C57/Bl6 Wild-type (WT) and APPswe/PS1dE9 (APP/PS1) mice, a well-established mouse model of familial AD. Our results indicate that the continuous HFD administration starting at the time of weaning is sufficient to produce ß-amyloid-independent, hippocampal-dependent memory deficits measured by a 2-object novel-object recognition test (NOR) in mice as early as 6months of age. Furthermore, the resulting metabolic syndrome appears to have direct effects on brain insulin regulation and mitochondrial function. We have observed pathological changes related to both the proximal and distal insulin signaling pathway in the brains of HFD-fed WT and APP/PS1 mice. These changes are accompanied by a significantly reduced OXPHOS metabolism, suggesting that mitochondria play an important role in hippocampus-dependent memory formation and retention in both the HFD-treated and AD-like rodents at a relatively young age.

16.
Tetrahedron Lett ; 56(10): 1272-1275, 2015 Mar 04.
Article in English | MEDLINE | ID: mdl-32287445

ABSTRACT

Two alternative syntheses of 2-oxaadamantan-5-amine, a novel analog of the clinically approved drug amantadine, are reported. The compound has been tested as an anti-influenza A virus agent and as an NMDA receptor antagonist. While the compound was not antivirally active, it displayed moderate activity as an NMDA receptor antagonist.

17.
Toxicol In Vitro ; 29(1): 59-62, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25238672

ABSTRACT

Marine dinoflagelates from the genus Dynophisis are important producers of Diarrhetic Shellfish Poisoning (DSP) toxins which are responsible for human intoxications. The present work is an approach to study the relative toxicity of DSP toxins effects on Neuro-2a, NG108-15 and MCF-7 cell-lines. Certified standards of okadaic acid (OA), dinophysistoxin-1 (DTX-1) and dinophysistoxin-2 (DTX-2) were used. Our results show that the three toxins exhibit similar cytotoxicity in Neuro-2a and NG108-15 cell lines. Conversely, MCF-7 cells were the least sensitive to these toxins. DTX-1 displayed the most toxic effect in the three tested cell lines.


Subject(s)
Marine Toxins/toxicity , Okadaic Acid/toxicity , Pyrans/toxicity , Cell Line , Dose-Response Relationship, Drug , Humans , MCF-7 Cells/drug effects
18.
Bioorg Med Chem Lett ; 24(15): 3333-6, 2014 Aug 01.
Article in English | MEDLINE | ID: mdl-24974339

ABSTRACT

N-Methyl-D-aspartate receptors (NMDAR) exacerbated activation leads to neuron death through a phenomenon called excitotoxicity. These receptors are implicated in several neurological diseases (e.g., Alzheimer and Parkinson) and thus represent an important therapeutic target. We herein describe the study of enantiopure tryptophanol-derived oxazolopiperidone lactams as NMDA receptor antagonists. The most active hit exhibited an IC50 of 63.4 µM in cultured rat cerebellar granule neurons thus being 1.5 fold more active than clinically approved NMDA antagonist amantadine (IC50=92 µM).


Subject(s)
Indoles/pharmacology , Lactams/pharmacology , Piperidones/pharmacology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Tryptophan/analogs & derivatives , Animals , Cerebellum/drug effects , Cerebellum/metabolism , Dose-Response Relationship, Drug , Indoles/chemical synthesis , Indoles/chemistry , Lactams/chemical synthesis , Lactams/chemistry , Molecular Structure , Neurons/drug effects , Neurons/metabolism , Piperidones/chemical synthesis , Piperidones/chemistry , Rats , Structure-Activity Relationship , Tryptophan/chemistry
19.
Biochim Biophys Acta ; 1842(9): 1556-66, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24887203

ABSTRACT

The present study had focused on the behavioral phenotype and gene expression profile of molecules related to insulin receptor signaling in the hippocampus of 3 and 6 month-old APPswe/PS1dE9 (APP/PS1) transgenic mouse model of Alzheimer's disease (AD). Elevated levels of the insoluble Aß (1-42) were detected in the brain extracts of the transgenic animals as early as 3 months of age, prior to the Aß plaque formation (pre-plaque stage). By the early plaque stage (6 months) both the soluble and insoluble Aß (1-40) and Aß (1-42) peptides were detectable. We studied the expression of genes related to memory function (Arc, Fos), insulin signaling, including insulin receptor (Insr), Irs1 and Irs2, as well as genes involved in insulin growth factor pathways, such as Igf1, Igf2, Igfr and Igfbp2. We also examined the expression and protein levels of key molecules related to energy metabolism (PGC1-α, and AMPK) and mitochondrial functionality (OXPHOS, TFAM, NRF1 and NRF2). 6 month-old APP/PS1 mice demonstrated impaired cognitive ability, were glucose intolerant and showed a significant reduction in hippocampal Insr and Irs2 transcripts. Further observations also suggest alterations in key cellular energy sensors that regulate the activities of a number of metabolic enzymes through phosphorylation, such as a decrease in the Prkaa2 mRNA levels and in the pAMPK (Thr172)/Total APMK ratio. Moreover, mRNA and protein analysis reveals a significant downregulation of genes essential for mitochondrial replication and respiratory function, including PGC-1α in hippocampal extracts of APP/PS1 mice, compared to age-matched wild-type controls at 3 and 6 months of age. Overall, the findings of this study show early alterations in genes involved in insulin and energy metabolism pathways in an APP/PS1 model of AD. These changes affect the activity of key molecules like NRF1 and PGC-1α, which are involved in mitochondrial biogenesis. Our results reinforce the hypothesis that the impairments in both insulin signaling and energy metabolism precede the development of AD amyloidogenesis.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Protein Precursor/physiology , Disease Models, Animal , Energy Metabolism , Hippocampus/metabolism , Mitochondria/metabolism , Presenilin-1/physiology , Alzheimer Disease/genetics , Alzheimer Disease/pathology , Amyloidogenic Proteins , Animals , Biomarkers/metabolism , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Hippocampus/pathology , Immunoenzyme Techniques , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Mitochondria/pathology , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction
20.
Bioorg Med Chem ; 22(9): 2678-83, 2014 May 01.
Article in English | MEDLINE | ID: mdl-24698811

ABSTRACT

A new series of benzopolycyclic amines active as NMDA receptor antagonists were synthesized. Most of them exhibited increased activity compared with related analogues previously published. All the tested compounds were more potent than clinically approved amantadine and one of them displayed a lower IC50 value than memantine, an anti-Alzheimer's approved drug.


Subject(s)
Amines/chemistry , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Amantadine/chemistry , Amantadine/metabolism , Amines/chemical synthesis , Amines/metabolism , Memantine/chemistry , Memantine/metabolism , Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/chemistry , Neuroprotective Agents/metabolism , Protein Binding , Receptors, N-Methyl-D-Aspartate/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...